drugset / Trial / NCT04479917

Efficacy and Safety of TPN171H in the Patients With Erectile Dysfunction

NCT04479917

RandomizedParallel-groupDouble-blindTreatment

Summary

This is an exploratory clinical study to presume the optimum usage and dosage for a therapeutic confirmatory study by evaluating the efficacy and safety of TPN171H 5mg, 10mg, 20mg or placebo administered orally in patients with erectile dysfunction. In conclusions, Patients with erectile dysfunction (ED) were administered placebo, TPN171H 5mg, 10mg or 20mg 30 minutes to 4 hours before sexual intercourse for 8 weeks.

Timeline

Start
2020-07-23
Primary completion
2021-07-26
Completion
2021-07-26

Drugs

EvaluationDrugModalityDoseRoute
Subject TPN171H Unknown 5 mg Oral
Subject TPN171H Unknown 10 mg Oral
Subject TPN171H Unknown 20 mg Oral

Indications